<DOC>
	<DOCNO>NCT00373945</DOCNO>
	<brief_summary>This retrospective case-control study conduct estimate sensitivity pharmacogenetic marker , HLA-B*5701 hypersensitivity abacavir ( ABC HSR ) . The specificity marker , association ABC HSR , measure odds ratio 95 % confidence interval , evaluate secondary endpoint . Cases define two way - subject clinically-suspected ABC HSR positive abacavir skin patch test reaction ( CS-SPTPos ) subject clinically-suspected ABC HSR ( CS-HSR ) , regardless result skin patch testing . The study include 40 CS-SPTPos Black case match 200 abacavir-tolerant control . In parallel , 40 CS-SPTPos White case match 200 White control . Some secondary analysis use case define clinical criterion alone ( CS-HSR ) . Black White subject analyze separately difference ABC HSR rate carriage frequency HLA-B*5701 .</brief_summary>
	<brief_title>HLA-B*5701 And Hypersensitivity To Abacavir</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion criterion : Subjects HIV1 infection clinicallysuspected hypersensitivity abacavir . Subjects must provide consent skin patch test pharmacogenetic evaluation . Exclusion criterion : Women find pregnant baseline . Subjects HIV1 infection tolerate abacavir least 12 week without experience hypersensitivity drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>HLA-B*5701</keyword>
	<keyword>pharmacogenetic marker</keyword>
	<keyword>hypersensitivity abacavir ,</keyword>
	<keyword>retrospective analysis</keyword>
</DOC>